THE Food and Drug Administration (FDA approved the issuance of an Emergency Use Authorization (EUA) to a new COVID-19 vaccine.
FDA Director-General Eric Domingo said the new vaccine is named Covovax, also called Novavax in the US.
Covovax is a protein sub unit vaccine according to Domingo, wherein pure antegenic part of the virus was used as a component of the vaccine.
Just like majority of the vaccine brands, two doses are needed in administering the vaccine with a gap of between 2-3 weeks.
He said that based on results of clinical trials, Covovax recorded an 89.7-percent efficacy rate and displayed very mild adverse effects.
Covovax can be added to the list of vaccine brands being used already in the country by the last part of the year or early 2022.